132645Study how SAMBA can help Ministries of Health expand HIV testing and treatment in AfricaClosedFeasibility StudiesInnovate UKDiagnostics for the Real World has developed a simple, robust, point-of-care nucleic acid test platform called SAMBA, which allows complex, high-performance tests to be carried out in remote, resource-limited settings in Africa or primary care settings in the UK and EU. The first SAMBA tests are for HIV: 1) viral load measure for treatment monitoring and 2) HIV detection in infants to initiate early treatment. With WHO recommendation and funding from aid organisations, the market for HIV testing to monitor and initiate treatment in Sub- Saharan Africa is estimated at $470 million for 2017-2019. Initial customers will be African Ministries of Health and organisations such as Médecins Sans Frontières (MSF). To promote SAMBA, DRW proposes to initially target Kenya, Uganda, Malawi and Zimbabwe and meet with their Ministries of Health to identify how SAMBA can benefit their HIV treatment programs for mothers and newborns, people in remote villages and improved HIV results monitoring. Study results will help further develop a customer-driven implementation plan.